Trial Profile
Phase II Trial of CC-5013 (Lenalidomide, Revlimid) in Patients With Cutaneous T-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- 22 Oct 2020 Status changed from active, no longer recruiting to completed.
- 01 May 2019 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
- 01 May 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.